JonesTrading analyst Soumit Roy maintains $Editas Medicine (EDIT.US)$ with a buy rating, and maintains the target price at $13.
According to TipRanks data, the analyst has a success rate of 22.3% and a total average return of -21.8% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Editas Medicine (EDIT.US)$'s main analysts recently are as follows:
The assessment of Editas Medicine's Q3 performance was marked as incremental in the wake of the company's strategic update.
The primary discussion among investors regarding Editas Medicine centers on the assessment of the company's new strategy as either progressive or regressive. The belief is that the company's reni-cel for sickle cell disease and transfusion-dependent thalassemia represents a less risky asset with potential for monetization. Moreover, this asset may provide critical insights that could influence future strategies for their in vivo candidates.
The emphasis on in vivo HSPC editing is viewed as a strategic utilization of Editas Medicine's expertise and resources to generate value. Anticipation is building for the forthcoming in vivo pipeline update in Q1 2025, along with further details on reni-cel BD activity.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
JonesTrading分析師Soumit Roy維持$Editas Medicine (EDIT.US)$買入評級，維持目標價13美元。
根據TipRanks數據顯示，該分析師近一年總勝率為22.3%，總平均回報率為-21.8%。
此外，綜合報道，$Editas Medicine (EDIT.US)$近期主要分析師觀點如下：
在公司戰略更新之後，對Editas Medicine第三季度業績的評估被標記爲漸進式評估。
投資者關於Editas Medicine的主要討論集中在評估該公司的新戰略是漸進式還是倒退式的。人們認爲，該公司用於治療鐮狀細胞病和依賴輸血的地中海貧血的reni-cel是一種風險較小的資產，具有獲利潛力。此外，該資產可能提供關鍵見解，可能會影響其體內候選產品的未來策略。
強調體內 HSPC 編輯被視爲戰略性地利用Editas Medicine的專業知識和資源來創造價值。人們對即將於2025年第一季度進行的體內產品線更新以及有關reni-cel BD活動的更多細節的期望越來越高。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
